Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species
- 4 January 2012
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 4 (115), 115ra2
- https://doi.org/10.1126/scitranslmed.3002925
Abstract
Simian adenoviruses screened from wild-derived candidates can prime T cell responses in man and may serve as new vaccine vector candidates.Keywords
This publication has 49 references indexed in Scilit:
- Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine VectorThe Journal of Infectious Diseases, 2012
- Adenovirus type-35 vectors block human CD4 + T-cell activation via CD46 ligationProceedings of the National Academy of Sciences of the United States of America, 2011
- Origin of the human malaria parasite Plasmodium falciparum in gorillasNature, 2010
- Novel adenovirus vector-based vaccines for HIV-1Current Opinion in HIV and AIDS, 2010
- Features of responding T cells in cancer and chronic infectionCurrent Opinion in Immunology, 2010
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisThe Lancet, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysNature, 2008
- Clustal W and Clustal X version 2.0Bioinformatics, 2007
- Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus VectorThe Journal of Infectious Diseases, 2006